Advances in the biology and treatment of Waldenström's macroglobulinemia: a report from the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden.

@article{Treon2009AdvancesIT,
  title={Advances in the biology and treatment of Waldenstr{\"o}m's macroglobulinemia: a report from the 5th International Workshop on Waldenstr{\"o}m's Macroglobulinemia, Stockholm, Sweden.},
  author={S. Treon and C. Patterson and E. Kimby and M. Stone},
  journal={Clinical lymphoma \& myeloma},
  year={2009},
  volume={9 1},
  pages={
          10-5
        }
}
The 5th International Workshop on Waldenstrom’s Macroglobulinemia (IWWM5) was held on October 15-19, 2008, in Stockholm, Sweden. The meeting was co-organized by Drs. Eva Kimby (Sweden) and Steven Treon (United States), who served as Co-Chairs, and Christopher Patterson (United States) who served as Organizing Secretariat. During the four-day meeting, over 80 invited speakers and young investigator award recipients presented their latest findings on the genetic basis, pathogenesis, and treatment… Expand
Novel treatment options for Waldenström macroglobulinemia.
Choice of therapy for patients with Waldenstrom macroglobulinemia.
  • I. Ghobrial
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study
Pathophysiology of Waldenström’s macroglobulinemia
...
1
2
...

References

SHOWING 1-10 OF 69 REFERENCES
Characterization of familial Waldenstrom's Macroglobulinemia.
Targeting CD40 in Waldenström's macroglobulinemia.
Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.
...
1
2
3
4
5
...